Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merus N.V. CS
(NQ:
MRUS
)
49.99
-0.94 (-1.85%)
Streaming Delayed Price
Updated: 2:41 PM EST, Nov 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merus N.V. CS
< Previous
1
2
3
4
5
Next >
5 Analysts Have This to Say About Merus
November 16, 2022
Via
Benzinga
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
November 09, 2022
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Third Quarter and Provides Business Update
November 03, 2022
From
Merus N.V.
Via
GlobeNewswire
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
October 26, 2022
From
Merus N.V.
Via
GlobeNewswire
What 4 Analyst Ratings Have To Say About Merus
October 13, 2022
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings:
Via
Benzinga
4 Analysts Have This to Say About Merus
October 13, 2022
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings:
Via
Benzinga
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus
January 26, 2022
Incyte Corporation (NASDAQ: INCY) is
Via
Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
November 04, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.
Via
Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
November 03, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.
Via
Benzinga
Albemarle To Rally Around 8%? Here Are 5 Other Price Target Changes For Thursday
October 13, 2022
Berenberg raised Albemarle Corporation (NYSE: ALB) price target from $260 to $270. Berenberg analyst Andres Castanos Mollor downgraded the stock from Buy to Hold. Albemarle shares fell 7.9% to close at...
Via
Benzinga
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
October 27, 2022
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the...
Via
Benzinga
Analyst Casts Doubts On Merus' Lung Candidate Safety Profile
October 12, 2022
Earlier today, Merus N.V. (NASDAQ: MRUS) announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small...
Via
Benzinga
Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session
October 26, 2022
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate...
Via
Benzinga
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
October 12, 2022
From
Merus N.V.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
August 02, 2022
Upgrades
Via
Benzinga
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90
July 14, 2022
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier.
Via
Investor's Business Daily
Needham Says Merus' ASCO Update On Zeno 'Positive'
June 06, 2022
Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer.
Via
Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
April 21, 2022
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.
Via
InvestorPlace
70 Biggest Movers From Friday
May 31, 2022
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...
Via
Benzinga
Promising Developments in Breast Cancer Treatments Ahead in 2022
January 12, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...
Via
FinancialNewsMedia
Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings
December 10, 2021
Merus NV (NASDAQ: MRUS) has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic...
Via
Benzinga
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
November 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Notable Merus Insider Makes $31M Sale
October 11, 2021
Mark Lampert, 10% Owner at Merus (NASDAQ:MRUS), made a large insider sell on October 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
45 Biggest Movers From Yesterday
October 08, 2021
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial...
Via
Benzinga
Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher
October 07, 2021
Toward the end of trading Thursday, the Dow traded up 1.29% to 34,860.01 while the NASDAQ rose 1.47% to 14,714.54. The S&P also rose, gaining 1.22% to 4,416.63. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Merus Stock Flirts With Breakout After Experimental Drug Shrinks All Tumors
October 07, 2021
Merus is flirting with a buy point on its strong, early-stage cancer test results.
Via
Investor's Business Daily
Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide
October 07, 2021
Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, gaining 1.41% to 4,425.22. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.